Galera Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: GRTX · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1563577
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: GRTX
TL;DR
Galera Therapeutics (GRTX) filed an 8-K on shareholder votes. Keep an eye on what they voted on.
AI Summary
Galera Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on matters submitted to a vote of security holders as of February 24, 2025. The filing indicates the company's principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355, with a phone number of 610-725-1500. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing signals that Galera Therapeutics has held or is reporting on a shareholder vote, which could pertain to significant corporate actions like mergers, acquisitions, or board elections.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can indicate significant corporate events that may impact stock price, requiring investor attention.
Key Numbers
- 001-39114 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-1454898 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- February 24, 2025 (date) — Date of earliest event reported
- February 25, 2025 (date) — Date of report
- 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 (address) — Principal executive offices
- 610-725-1500 (phone_number) — Registrant's telephone number
- Delaware (jurisdiction) — State of incorporation
- 2834 (sic_code) — Standard Industrial Classification
FAQ
What specific matters were submitted to a vote of Galera Therapeutics' security holders?
The filing states that the report is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and is a 'CURRENT REPORT' concerning 'Submission of Matters to a Vote of Security Holders'. However, the specific details of the matters voted upon are not elaborated in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 24, 2025.
What is the principal business address of Galera Therapeutics, Inc.?
The principal executive offices of Galera Therapeutics, Inc. are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
In which state is Galera Therapeutics, Inc. incorporated?
Galera Therapeutics, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification (SIC) code for Galera Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Galera Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Galera Therapeutics, Inc. (GRTX).